$3.11
Insights on Mdxhealth Sa
Revenue is up for the last 10 quarters, 5.49M → 19.39M (in $), with an average increase of 12.4% per quarter
Netprofit is down for the last 2 quarters, -10.04M → -10.72M (in $), with an average decrease of 6.7% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 20.7% return, outperforming this stock by 43.0%
Market Capitalization | 67.4M |
Book Value | $0.26 |
Earnings Per Share (EPS) | -2.1 |
Wall Street Target Price | 8.4 |
Profit Margin | -61.4% |
Operating Margin TTM | -32.51% |
Return On Assets TTM | -13.76% |
Return On Equity TTM | -521.7% |
Revenue TTM | 70.2M |
Revenue Per Share TTM | 2.7 |
Quarterly Revenue Growth YOY | 50.5% |
Gross Profit TTM | 19.2M |
EBITDA | -20.5M |
Diluted Eps TTM | -2.1 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.02 |
EPS Estimate Next Year | -0.65 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.11 |
What analysts predicted
Upside of 170.1%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 28.3M | ↓ 30.04% |
Net Income | -32.5M | ↑ 164.08% |
Net Profit Margin | -114.51% | ↓ 84.18% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 11.8M | ↓ 58.41% |
Net Income | -43.1M | ↑ 32.82% |
Net Profit Margin | -365.72% | ↓ 251.21% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 18.4M | ↑ 55.89% |
Net Income | -30.0M | ↓ 30.38% |
Net Profit Margin | -163.33% | ↑ 202.39% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 22.2M | ↑ 21.05% |
Net Income | -30.9M | ↑ 2.9% |
Net Profit Margin | -138.84% | ↑ 24.49% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 37.1M | ↑ 66.62% |
Net Income | -50.2M | ↑ 62.54% |
Net Profit Margin | -135.45% | ↑ 3.39% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 70.2M | ↑ 89.43% |
Net Income | -43.1M | ↓ 14.12% |
Net Profit Margin | -61.4% | ↑ 74.05% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.2M | ↑ 61.58% |
Net Income | -13.5M | ↑ 37.3% |
Net Profit Margin | -121.05% | ↑ 21.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 12.9M | ↑ 15.57% |
Net Income | -12.4M | ↓ 7.88% |
Net Profit Margin | -96.49% | ↑ 24.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.7M | ↑ 14.03% |
Net Income | -14.7M | ↑ 18.19% |
Net Profit Margin | -100.01% | ↓ 3.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.7M | ↑ 13.91% |
Net Income | -10.6M | ↓ 27.72% |
Net Profit Margin | -63.46% | ↑ 36.55% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 19.4M | ↑ 15.56% |
Net Income | -10.0M | ↓ 5.47% |
Net Profit Margin | -51.91% | ↑ 11.55% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 19.4M | ↑ 0.25% |
Net Income | -10.7M | ↑ 6.72% |
Net Profit Margin | -55.26% | ↓ 3.35% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 65.5M | ↑ 11.88% |
Total Liabilities | 13.4M | ↓ 10.79% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 40.6M | ↓ 37.95% |
Total Liabilities | 20.9M | ↑ 56.48% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 31.9M | ↓ 21.59% |
Total Liabilities | 26.0M | ↑ 24.41% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 75.1M | ↑ 135.66% |
Total Liabilities | 28.2M | ↑ 8.33% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 119.1M | ↑ 58.69% |
Total Liabilities | 109.8M | ↑ 289.81% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 129.1M | ↑ 8.39% |
Total Liabilities | 121.9M | ↑ 11.02% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 122.6M | ↑ 109.49% |
Total Liabilities | 101.1M | ↑ 251.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 119.1M | ↓ 2.81% |
Total Liabilities | 109.8M | ↑ 8.63% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 150.8M | ↑ 26.57% |
Total Liabilities | 113.1M | ↑ 3.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 142.5M | ↓ 5.47% |
Total Liabilities | 115.9M | ↑ 2.43% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 135.7M | ↓ 4.78% |
Total Liabilities | 117.9M | ↑ 1.73% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 129.1M | ↓ 4.86% |
Total Liabilities | 121.9M | ↑ 3.42% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.5M | ↑ 172.12% |
Investing Cash Flow | -1.3M | ↓ 77.45% |
Financing Cash Flow | 41.7M | ↑ 7172.6% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.3M | ↓ 21.91% |
Investing Cash Flow | -73.0K | ↓ 94.57% |
Financing Cash Flow | 18.0M | ↓ 56.89% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.2M | ↓ 9.17% |
Investing Cash Flow | -537.0K | ↑ 635.62% |
Financing Cash Flow | 14.3M | ↓ 20.46% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.5M | ↑ 11.38% |
Investing Cash Flow | -1.2M | ↑ 124.95% |
Financing Cash Flow | 66.5M | ↑ 365.35% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -34.1M | ↑ 51.31% |
Investing Cash Flow | -29.2M | ↑ 2314.16% |
Financing Cash Flow | 20.8M | ↓ 68.66% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.3M | ↑ 44.43% |
Investing Cash Flow | -25.6M | - |
Financing Cash Flow | 22.5M | ↓ 2912.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.7M | ↑ 4.5% |
Investing Cash Flow | -2.2M | ↓ 91.24% |
Financing Cash Flow | -20.0K | ↓ 100.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.3M | ↓ 56.1% |
Investing Cash Flow | -1.2M | ↓ 44.58% |
Financing Cash Flow | 38.3M | ↓ 191430.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.6M | ↑ 31.04% |
Investing Cash Flow | -1.6M | ↑ 26.73% |
Financing Cash Flow | -1.4M | ↓ 103.73% |
Sell
Neutral
Buy
Mdxhealth Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Mdxhealth Sa | 21.48% | -89.97% | -22.25% | -74.08% | -74.08% |
Idexx Laboratories, Inc. | -6.03% | 13.08% | -0.38% | -7.92% | 96.79% |
Agilent Technologies Inc. | -2.21% | 29.14% | 6.66% | 7.13% | 84.4% |
Thermo Fisher Scientific, Inc. | -1.02% | 26.1% | 5.58% | 23.6% | 111.77% |
Danaher Corp. | 1.85% | 26.39% | 3.98% | -3.96% | 88.86% |
Iqvia Holdings Inc. | -5.12% | 14.71% | 20.71% | -1.02% | 72.0% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Mdxhealth Sa | NA | NA | NA | -1.02 | -5.22 | -0.14 | NA | 0.26 |
Idexx Laboratories, Inc. | 49.03 | 49.03 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 32.89 | 32.89 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.35 | 37.35 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 45.86 | 45.86 | 3.13 | 7.63 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.18 | 32.18 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Mdxhealth Sa | Buy | $67.4M | -74.08% | NA | -61.4% |
Idexx Laboratories, Inc. | Buy | $41.1B | 96.79% | 49.03 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 84.4% | 32.89 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $220.4B | 111.77% | 37.35 | 13.99% |
Danaher Corp. | Buy | $185.5B | 88.86% | 45.86 | 18.55% |
Iqvia Holdings Inc. | Buy | $42.8B | 72.0% | 32.18 | 9.06% |
Alyeska Investment Group, L.P.
Mdxhealth Sa’s price-to-earnings ratio stands at None
Read MoreOrganization | Mdxhealth Sa |
Employees | 0 |
CEO | Mr. Michael K. McGarrity |
Industry | Healthcare |